Identification of RCN3-positive cancer-associated fibroblasts as novel drivers of colorectal cancer through a TGF-β pathway-based risk signature
Comprehensive multi-omics mapping links heightened TGF-β activity and a distinct consensus-clustering subtype to unfavorable outcomes and immunotherapy resistance in CRC. The externally validated TGFRS offers a practical prognostic and predictive tool. RCN3⁺ CAFs constitute key stromal drivers, and dasatinib emerges as a repurposable agent to disrupt this axis, warranting clinical exploration.
Authors
- Shangshang Hu (ORCID: https://orcid.org/0009-0009-3828-9907)
- Nannan Wang (ORCID: https://orcid.org/0009-0007-7135-1560)
- Linlin Zhu (ORCID: https://orcid.org/0000-0001-8932-9758)
- Biao Gu (ORCID: https://orcid.org/0000-0002-5560-9388)
- Weichun Tang (ORCID: https://orcid.org/0000-0003-0796-6038)
- Qiang Li (ORCID: https://orcid.org/0000-0002-2354-177X)
- Pengpeng Xu (ORCID: https://orcid.org/0000-0002-1283-0779)
Institutions
- Bengbu Medical College (CN)
- Anhui Science and Technology University (CN)
- The Second Affiliated Hospital of Bengbu Medical College (CN)
- Southeast University (CN)
- Henan Medical University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2025-11-04
- DOI
- https://doi.org/10.1097/js9.0000000000003825
- Primary Topic
- TGF-β signaling in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00